Sara
Villar Fernández
Colaboradora Clínica
Fundación Jiménez Díaz
Madrid, España
Publications in collaboration with researchers from Fundación Jiménez Díaz (9)
2025
-
Allo-HCT refined ELN 2022 risk classification: validation of the Adverse-Plus risk group in AML patients undergoing allogeneic hematopoietic cell transplantation within the Spanish Group for Hematopoietic Cell Transplantation (GETH-TC)
Blood Cancer Journal, Vol. 15, Núm. 1
-
Frailty dynamics and their impact on QoL in patients undergoing autologous HCT for multiple myeloma: Results from a multicentre GETH-TC study
British Journal of Haematology, Vol. 207, Núm. 4, pp. 1504-1516
-
Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation
Cancers, Vol. 17, Núm. 19
2024
-
Cardiac events after allo-HCT in patients with acute myeloid leukemia
Blood Advances, Vol. 8, Núm. 21, pp. 5497-5509
-
Cardiac events occurring after allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide. Study conducted on behalf of the GETH-TC
Bone Marrow Transplantation, Vol. 59, Núm. 12, pp. 1694-1703
-
Data-driven flow cytometry classification of blast differentiation in older patients with acute myeloid leukemia
Blood Neoplasia, Vol. 1, Núm. 3
-
Frailty assessment in adults undergoing allogeneic hematopoietic cell transplantation: insights from a multicenter GETH-TC study to optimize outcomes and care
Frontiers in Immunology, Vol. 15
2023
-
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia
British Journal of Haematology
2021
-
Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial
Blood Advances, Vol. 5, Núm. 3, pp. 760-770